Sio Gene Therapies, Inc. (SIOX) News

Sio Gene Therapies, Inc. (SIOX): $1.97

-0.03 (-1.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SIOX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

Filter SIOX News Items

SIOX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SIOX News Highlights

  • SIOX's 30 day story count now stands at 8.
  • Over the past 28 days, the trend for SIOX's stories per day has been choppy and unclear. It has oscillated between 2 and 3.
  • The most mentioned tickers in articles about SIOX are GENE.

Latest SIOX News From Around the Web

Below are the latest news stories about Sio Gene Therapies Inc that investors may wish to consider to help them evaluate SIOX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, investor!

William White on InvestorPlace | October 21, 2021

Sio Gene Therapies Announces Reorganization of R&D Group

Two new executive positions created in connection with departure of R&D HeadNEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, announced today that Gavin Corcoran, M.D., Chief Research and Development Officer, will be leaving the company effective November 12, 2021, to pursue an opportunity with a private hea

Yahoo | October 21, 2021

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of Type I (early infantile-onset) and Type II (late inf

Yahoo | October 21, 2021

Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis

Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSW

Yahoo | October 21, 2021

UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosisNEW YORK, and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new clinical and preclinical data in two oral presen

Yahoo | October 4, 2021

Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosisNEW YORK and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new clinical and preclinical data in two oral present

Yahoo | October 4, 2021

Sio Gene Therapies to Participate in Upcoming Conferences

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.

Intrado Digital Media | September 23, 2021

Quite a few insiders invested in Sio Gene Therapies Inc. (NASDAQ:SIOX) last year which is positive news for shareholders

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Yahoo | September 13, 2021

Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy

- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts- On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 cohort in October 2021 NEW YORK, and DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced dosing of the first Ty

Yahoo | September 9, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Good morning, investor!

William White on InvestorPlace | August 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.7036 seconds.